Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Disc Medicine Inc

Contributing Author

Recent Articles by Disc Medicine Inc

Sep-02
Disc Medicine to Participate in Upcoming Investor Conferences IRON GlobeNewswire
Aug-31
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting IRON GlobeNewswire
Jul-30
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update IRON +7.52% GlobeNewswire
Jun-12
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting IRON GlobeNewswire
Jun-09
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria IRON GlobeNewswire
Jun-02
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting IRON -5.52% GlobeNewswire
Jun-01
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients IRON GlobeNewswire
May-12
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress IRON GlobeNewswire
May-11
Disc Medicine to Participate in Upcoming Investor Conferences IRON GlobeNewswire
May-05
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update IRON GlobeNewswire
Apr-21
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting IRON GlobeNewswire
Mar-26
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria IRON GlobeNewswire
Feb-26
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update IRON GlobeNewswire
Feb-24
Disc Medicine to Participate in Upcoming Investor Conferences IRON GlobeNewswire
Feb-13
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP IRON -21.91% IRON +17.19% GlobeNewswire
Jan-12
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer IRON GlobeNewswire
Jan-12
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 IRON GlobeNewswire
Jan-07
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference IRON GlobeNewswire
Dec-06
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting IRON GlobeNewswire
Nov-06
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update IRON GlobeNewswire
Nov-03
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting IRON GlobeNewswire
Oct-31
Disc Medicine to Participate in Upcoming Investor Conferences IRON GlobeNewswire
Oct-21
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants IRON GlobeNewswire
Oct-20
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IRON GlobeNewswire
Oct-20
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones IRON GlobeNewswire
Oct-17
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week IRON +20.95% GlobeNewswire
Oct-16
Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) IRON GlobeNewswire
Sep-30
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) IRON GlobeNewswire
Aug-27
Disc Medicine to Participate in Upcoming Investor Conferences IRON GlobeNewswire
Aug-07
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update IRON GlobeNewswire
Jul-21
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 IRON GlobeNewswire
Jul-14
Disc Medicine Appoints Nadim Ahmed to its Board of Directors IRON GlobeNewswire
Jun-12
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress IRON GlobeNewswire
May-28
Disc Medicine to Participate in Upcoming Investor Conferences IRON GlobeNewswire
May-14
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress IRON GlobeNewswire
May-13
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference IRON GlobeNewswire
May-07
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update IRON GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)